Solid Biosciences Inc. financial data

Symbol
SLDB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 Rutherford Avenue, 3 Rd Floor, Charlestown, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Solid Biosciences, LLC (to 1/25/2018)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 911 % -4.74%
Debt-to-equity 24.3 % -9.37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.5M shares +105%
Common Stock, Shares, Outstanding 40.5M shares +98.5%
Entity Public Float 130M USD +153%
Common Stock, Value, Issued 40K USD +100%
Weighted Average Number of Shares Outstanding, Basic 40.8M shares +105%
Weighted Average Number of Shares Outstanding, Diluted 40.8M shares +105%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 96.4M USD +26%
General and Administrative Expense 33.3M USD +20%
Operating Income (Loss) -130M USD -24.4%
Nonoperating Income (Expense) 5.03M USD -38.9%
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -3.06 USD/shares +36.6%
Earnings Per Share, Diluted -3.06 USD/shares +36.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 80.2M USD +8.4%
Cash, Cash Equivalents, and Short-term Investments 149M USD +20.4%
Assets, Current 157M USD +21.3%
Property, Plant and Equipment, Net 4.75M USD -28.3%
Operating Lease, Right-of-Use Asset 24.3M USD -8.46%
Other Assets, Noncurrent 366K USD +75.1%
Assets 189M USD +14.4%
Accounts Payable, Current 4.24M USD +109%
Accrued Liabilities, Current 19.9M USD +95.4%
Liabilities, Current 30.3M USD +108%
Operating Lease, Liability, Noncurrent 21.2M USD -6.82%
Liabilities 51.4M USD +33.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 47K USD +213%
Retained Earnings (Accumulated Deficit) -783M USD -18.9%
Stockholders' Equity Attributable to Parent 137M USD +8.51%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 126M USD -40.2%
Liabilities and Equity 189M USD +14.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.2M USD +10%
Net Cash Provided by (Used in) Financing Activities 107M USD
Net Cash Provided by (Used in) Investing Activities -38.5M USD -203%
Common Stock, Shares Authorized 120M shares +100%
Common Stock, Shares, Issued 40.5M shares +98.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 43.6M USD +370%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 82.2M USD +8.36%
Deferred Tax Assets, Valuation Allowance 131M USD +42.5%
Deferred Tax Assets, Gross 137M USD +38%
Operating Lease, Liability 22.9M USD -6.58%
Depreciation 2.58M USD +7.18%
Payments to Acquire Property, Plant, and Equipment 149K USD -70.6%
Lessee, Operating Lease, Liability, to be Paid 34.2M USD -10.8%
Property, Plant and Equipment, Gross 17.8M USD -8.19%
Operating Lease, Liability, Current 1.79M USD -3.67%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.28M USD +4.23%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.18M USD -5.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.3M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.28M USD +3.81%
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD +124%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.36M USD +2.95%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 10.5M USD +38%
Interest Expense 88K USD -20.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%